Company news
Sutro Biopharma, Inc. (NASDAQ:STRO) news
Sutro Biopharma, Inc. news releases on 6ix. Latest, Sep 29, 2026: Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Press releases & updates
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
September 29, 2026
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
September 28, 2026
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
August 12, 2026
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
May 14, 2026
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
April 19, 2026
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
March 22, 2026
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
February 23, 2026
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
February 10, 2026
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 17, 2025
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2025
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
December 3, 2025
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
December 1, 2025
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
November 12, 2025
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
November 6, 2025
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
November 5, 2025
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
November 3, 2025
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
September 29, 2025
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
August 7, 2025
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates
July 22, 2025
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
June 2, 2025
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
May 8, 2025
Sutro Biopharma to Participate in Upcoming Investor Conferences
May 1, 2025
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
April 28, 2025
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
March 15, 2025
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
March 13, 2025
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
March 13, 2025
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
March 3, 2025
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale
January 6, 2025
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
December 9, 2024
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
November 12, 2024
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
October 31, 2024
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2024
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
September 13, 2024
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
September 10, 2024
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
August 21, 2024
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
August 12, 2024
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
July 8, 2024
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
May 12, 2024
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
April 29, 2024
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
April 1, 2024
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
March 24, 2024
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
December 10, 2023
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
November 20, 2023
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
November 12, 2023
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
October 21, 2023
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
October 15, 2023
Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
September 18, 2023
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
August 9, 2023
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration
June 25, 2023